Research record / starter review

Ipamorelin

Growth-hormone secretagogue

Tested-sport concernLast reviewed 2026-07-13

Also called

Ipamorelin acetate · growth-hormone secretagogue

What people ask about

Community claims

growth-hormone claimsrecovery claims

These are topics circulating in appearance, physique, or recovery communities. Listing them does not validate them.

What this record can say

Evidence snapshot

A phase-II postoperative-ileus study in surgical patients reported no significant difference versus placebo in key or secondary efficacy analyses. It does not test body composition, athletic recovery, or appearance claims.

Safety context

Read uncertainty as information

FDA notes peptide-characterisation and immunogenicity concerns and says it lacks safety information for certain proposed injectable routes; its table also describes a serious adverse-event report in a specific intravenous clinical context.

Tested sport

Anti-doping context

WADA's 2026 List names ipamorelin among growth-hormone secretagogues and their mimetics in S2.2.4.

Regulatory scope

Context is not a universal answer

United States: this reflects FDA's compounding-safety source, not a global legal determination.

Study-level evidence

What the individual records actually say.

Every row preserves identity and context. A related molecule, a tissue experiment, or a trial registration cannot become proof for the community claim.

Published phase-II randomised placebo-controlled clinical trial2014

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients ↗

PMID: 25331030.

Identity: Exact compound name: ipamorelin

Design & population: Multicentre, double-blind, placebo-controlled postoperative study; 114 people were included in the safety and modified intention-to-treat populations.

Question studied: Postoperative gastrointestinal recovery after bowel resection, not athletic or musculoskeletal recovery.

Record finding: The report found no statistically significant difference between ipamorelin and placebo in its key or secondary efficacy analyses.

Does not show: It does not test body composition, muscle gain, fitness recovery, appearance, or long-term safety. A result in this surgical population cannot be repurposed as evidence for those claims.

Direct human clinical evidence — different indication; no significant efficacy result reportedChecked 2026-07-13

Primary sources

Read the source, not only our summary.

regulatory / safetyCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration ↗anti-doping2026 Prohibited ListWorld Anti-Doping Agency ↗